EOLS logo

Evolus, Inc.

EOLS
Healthcare|Drug Manufacturers - Specialty & Generic|US
$6.80
+0.01 (+0.15%)
DCF Value
$9.13
Cash / Share
$0.63

Clinical Trials (10)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT06903975
BoTox Into the Sternocleidomastoid Muscles (SCM)
Neck Muscle Issue
P4
Recruiting30Open-labelprabotulinumtoxinA-xvfs
NCT02334423
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
Glabellar Frown Lines
P3
Completed330RCT, Double-blindBotulinum toxin, Type A
NCT02334436
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002
Glabellar Frown Lines
P3
Completed324RCT, Double-blindBotulinum toxin, Type A
NCT02428608
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
Glabellar Frown Lines
P2
Completed570Open-labelDWP-450 (Botulinum purified neurotoxin, Type A)
NCT02184988
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
Glabellar Frown Lines
P2
Completed352Open-labelBotulinum purified neurotoxin, Type A
NCT05320393
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Glabellar Frown Lines
P2
Completed154RCT, Double-blindPrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA, PrabotulinumtoxinA-Xvfs
NCT06604832
Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture
Skin Aging, Skin Wrinkling
P1
Completed20RCT, Double-blindPrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, saline solution (placebo)
NCT05481931
Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Glabellar Frown Lines
Completed756—prabotulinumtoxinA
NCT05807412
Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides
Rhytides
Early P1
Completed10RCT, Double-blindPrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
NCT05129319
Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD
Glabellar Frown Lines
Early P1
Completed30RCT, Double-blindprabotulinumtoxinA